+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

European Neurological Disorder Drugs Market 2020-2026

  • ID: 5240945
  • Report
  • April 2020
  • Region: Europe
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021
1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • MORE
Europe Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026.

The European neurological disorder drug market is projected to grow at a significant CAGR during the forecast period (2020-2026). The key factors driving the growth of the market include the rising prevalence of neurological disorders among the people across the region. As per the European Academy of Neurology 2019, more than half of the population in Europe suffers from a neurological disorder. The mortality rate and disease burden due to neurological diseases is high in the region and ranks third among other diseases in the region. The rising geriatric population is another major reason for the increasing demand for neurological disorder drugs in the region. Elder people are more prone to diseases and such neurological disorders, thus creating a wide scope for the European neurological disorder drugs market.

The European neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.

Geographically, the European neurological disorder drugs market is analyzed into UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK is estimated to grow significantly during the forecast period. Further, Novartis International AG, Allergan Plc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, and F. Hoffmann-La Roche Ltd., are some of the prominent players operating in the European neurological disorder drugs market.

Research Methodology

The market study of the European neurological disorder drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for the pharmaceutical industry, drug manufacturers, hospitals & clinics, research organizations, academic institutes, non-profit organizations, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Europe Neurological Disorder Drugs Market Research and Analysis by Disorder Type

The Report Covers:
  • Comprehensive research methodology of the European Neurological Disorder Drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European Neurological Disorder Drugs market.
  • Insights about market determinants which are stimulating the European Neurological Disorder Drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • AstraZeneca Plc
  • Bayer AG
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Major Drug Analysis
  • Analgesics
  • Antidepressants
  • Sedatives & Hypnotics
  • Antihypertensive
  • Others
2.3. Analyst Insight & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendations
2.3.3. Conclusion
2.4. Rules & Regulations

3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities

4. Market Segmentation
4.1. Europe Neurological Disorder Drugs Market by Disorder Type
4.1.1. Epilepsy
4.1.2. Alzheimer’s Disease
4.1.3. Parkinson’s Disease
4.1.4. Multiple Sclerosis
4.1.5. Huntington Disease
4.1.6. Others

5. Regional Analysis
5.1. UK
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. Rest of Europe

6. Company Profiles
6.1. Allergan Plc
6.2. AstraZeneca Plc
6.3. Bayer AG
6.4. Boehringer Ingelheim International GmbH
6.5. Eli Lilly and Co.
6.6. F. Hoffmann-La Roche Ltd.
6.7. GlaxoSmithKline Plc
6.8. Novartis International AG
6.9. Sanofi SA
6.10. Sun Pharmaceutical Industries Ltd.
6.11. Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
3 of 3
  • Allergan Plc
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Novartis International AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll